Emerging mechanisms to modulate VWF release from endothelial cells.

Area of Science:

• Endothelial cell biology
• Hemostasis and thrombosis
• Vascular pathology

Background:

• Weibel-Palade bodies (WPBs) are crucial for endothelial response to injury via releasing von Willebrand factor (VWF).
• VWF multimers form platelet-aggregating strings, essential for hemostasis but linked to thrombotic diseases like myocardial infarction and stroke.
• Dysfunctional VWF string cleavage causes thrombotic thrombocytopenic purpura (TTP), a severe condition historically treated with plasma exchange.

Purpose of the Study:

• To review the potential of targeting Weibel-Palade bodies to inhibit VWF release.
• To explore novel therapeutic strategies for VWF-related cardiovascular diseases.
• To discuss progress and challenges in modulating WPB function for therapeutic benefit.

Main Methods:

• Review of current literature on WPB biogenesis, secretion, and VWF release.
• Analysis of emerging therapeutic paradigms targeting WPBs.
• Discussion of clinical advancements in treating VWF-related disorders.

Main Results:

• Excessive VWF levels are associated with thrombotic pathologies.
• Failure in VWF string cleavage leads to TTP.
• Newer treatments like Rituximab and Caplacizumab show promise for TTP, indicating improved understanding of VWF pathophysiology.

Conclusions:

• Targeting WPB exocytosis presents a promising therapeutic avenue for cardiovascular diseases by limiting VWF release.
• Understanding WPB biogenesis and secretory pathways is key to developing novel VWF release inhibitors.
• Modulating WPB size, trafficking, and fusion mechanisms are emerging strategies for controlling VWF release from endothelial cells.